Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.

The pharmacogenomics journal - 1 Jun 2012

Liu W, Downing A C M, Munsie L M, Chen P, Reed M R, Ruble C L, Landschulz K T, Kinon B J, Nisenbaum L K

Abstract excerpt

The goal of this study was to identify genetic markers associated with LY2140023 monohydrate response in patients with schizophrenia. Variants in eight candidate genes related to the mechanism of action of LY2140023 or olanzapine were investigated in a genetic cohort collected from two clinical trials. Results from this genetic analysis indicate that 23 single nucleotide polymorphisms (SNPs) were associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Benzodiazepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Excitatory Amino Acid Agonists

Share to Neuregulin-1

Share to Olanzapine

Share to Receptor, Serotonin, 5-HT2A

Share to Receptors, Metabotropic Glutamate

Share to Schizophrenic Psychology

Source

Identifiers

PMID: 21173788
DOI: 10.1038/tpj.2010.90

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.PMID 21173788Read ↗

Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia PatientsSemantic proximity Read ↗

Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.Semantic proximity Read ↗

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.Semantic proximity Read ↗

Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia.Semantic proximity Read ↗

Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients.Semantic proximity Read ↗

Association analysis of GRM2 and HTR2A with methamphetamine-induced psychosis and schizophrenia in the Japanese population.Semantic proximity Read ↗

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.Semantic proximity Read ↗

An Association of SLC2A9 variant rs7442295 with Uric Acid at Baseline and in Interaction with IloperidoneSemantic proximity Read ↗

A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone.Semantic proximity Read ↗

Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients.Semantic proximity Read ↗

Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia.Semantic proximity Read ↗

Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.